Home > Dermatology > AAD 2018 > Late-breakers > Behcet’s Syndrome and hidradenitis suppurativa

Behcet’s Syndrome and hidradenitis suppurativa

Presented By
Dr Yusuf Yazici, New York University School of Medicine
Conference
AAD 2018
Trial
RELIEF

Apremilast effective in Behcet´s Syndrome

The oral phosphodiesterase (PDE)4 inhibitor apremilast displayed a significant effect on ulcers and ulcer pain associated with Behcet´s syndrome in the RELIEF trial [16]. Behcet´s syndrome is a rare, chronic, multi-system inflammatory disorder characterised by oral and genital ulcers, skin lesions, uveitis, arthritis, with vascular, central nervous system, and gastrointestinal involvement.

A key symptom occurring in nearly all patients is painful recurrent oral ulcers that can be disabling and have a substantial effect on QoL: there are currently no effective treatment options for them. The oral PDE4 inhibitor apremilast modulates inflammatory mediators and has demonstrated efficacy in a Phase 2 Behcet´s syndrome study. These preliminary data were the reason for a Phase 3 trial with apremilast.

In the RELIEF study, a total of 207 patients were randomised to apremilast (30 mg twice daily) or placebo. A...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on